Main content 1 Menu 2 Search 3 Footer 4
+A
A
-A
High contrast
HOME JOURNAL CRITERIA NETWORK HELP ABOUT

Current criteria:

Regional:

WPRlM journal selection criteria(2023)

Minimum standards for the suspension and removal of WPRIM approved journals

Countries journal selection criteria:

Philippines

Submit your journal information>

Contact NJSCs>

Experimental & Molecular Medicine

1964  to  Present  ISSN: 1226-3613

Articles

About

Year of publication

Save Email

Sort by

Best match
Relevance
PubYear
JournalTitle

DISPLAY OPTIONS

Format:

Per page:

Save citations to file

Selection:

Format:

Create file Cancel

Email citations

To:

Please check your email address first!

Selection:

Format:

Send email Cancel

1579

results

page

of 158

1

Cite

Cite

Copy

Share

Share

Copy

Accumulation of argpyrimidine, a methylglyoxal-derived advanced glycation end product, increases apoptosis of lens epithelial cells both in vitro and in vivo.

Junghyun KIM ; Ohn Soon KIM ; Chan Sik KIM ; Eunjin SOHN ; Kyuhyung JO ; Jin Sook KIM

Experimental & Molecular Medicine.2012;44(2):167-175. doi:10.3858/emm.2012.44.2.012

The formation of advanced glycation end products (AGEs) has been considered to be a potential causative factor of injury to lens epithelial cells (LECs). Damage of LECs is believed to contribute to cataract formation. The purpose of this study was to investigate the cytotoxic effect of AGEs on LECs both in vitro and in vivo. We examined the accumulation of argpyrimidine, a methylglyoxal-derived AGE, and the expression of apoptosis-related molecules including nuclear factor-kappaB (NF-kappaB), Bax, and Bcl-2 in the human LEC line HLE-B3 and in cataractous lenses of Zucker diabetic fatty (ZDF) rats, an animal model of type 2 diabetes. In cataractous lenses from twenty-one-week-old ZDF rats, LEC apoptosis was markedly increased, and the accumulation of argpyrimidine as well as subsequent activation of NF-kappaB in LECs were significantly enhanced. The ratio of Bax to Bcl-2 protein levels was also increased. In addition, the accumulation of argpyrimidine triggered apoptosis in methylglyoxal-treated HLE-B3 cells. However, the presence of pyridoxamine (an AGEs inhibitor) and pyrrolidine dithiocarbamate (a NF-kappaB inhibitor) prevented apoptosis in HLE-B3 cells through the inhibition of argpyrimidine formation and the blockage of NF-kappaB nuclear translocalization, respectively. These results suggest that the cellular accumulation of argpyrimidine in LECs is NF-kappaB-dependent and pro-apoptotic.
Animals ; Apoptosis/*drug effects ; Cell Line ; Epithelial Cells/*cytology/*drug effects ; Glycosylation End Products, Advanced/*pharmacology ; Lens, Crystalline/*cytology ; Male ; Ornithine/*analogs & derivatives/pharmacology ; Pyrimidines/*pharmacology ; Pyruvaldehyde/*chemistry ; Rats

Animals ; Apoptosis/*drug effects ; Cell Line ; Epithelial Cells/*cytology/*drug effects ; Glycosylation End Products, Advanced/*pharmacology ; Lens, Crystalline/*cytology ; Male ; Ornithine/*analogs & derivatives/pharmacology ; Pyrimidines/*pharmacology ; Pyruvaldehyde/*chemistry ; Rats

2

Cite

Cite

Copy

Share

Share

Copy

Simvastatin inhibits sphingosylphosphorylcholine-induced differentiation of human mesenchymal stem cells into smooth muscle cells.

Kyung Hye KIM ; Young Mi KIM ; Mi Jeong LEE ; Hyun Chang KO ; Moon Bum KIM ; Jae Ho KIM

Experimental & Molecular Medicine.2012;44(2):159-166. doi:10.3858/emm.2012.44.2.011

Sphingosylphosphorylcholine (SPC) induces differentiation of human adipose tissue-derived mesenchymal stem cells (hASCs) into smooth muscle-like cells expressing alpha-smooth muscle actin (alpha-SMA) via transforming growth factor-beta1/Smad2- and RhoA/Rho kinase-dependent mechanisms. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) have been known to have beneficial effects in the treatment of cardiovascular diseases. In the present study, we examined the effects of simvastatin on the SPC-induced alpha-SMA expression and Smad2 phosphorylation in hASCs. Simvastatin inhibited the SPC-induced alpha-SMA expression and sustained phosphorylation of Smad2 in hASCs. SPC treatment caused RhoA activation via a simvastatin-sensitive mechanism. The SPC-induced alpha-SMA expression and Smad2 phosphorylation were abrogated by pretreatment of the cells with the Rho kinase inhibitor Y27632 or overexpression of a dominant negative RhoA mutant. Furthermore, SPC induced secretion of TGF-beta1 and pretreatment with either Y27632 or simvastatin inhibited the SPC-induced TGF-beta1 secretion. These results suggest that simvastatin inhibits SPC-induced differentiation of hASCs into smooth muscle cells by attenuating the RhoA/Rho kinase-dependent activation of autocrine TGF-beta1/Smad2 signaling pathway.
Amides/pharmacology ; Blotting, Western ; Cell Differentiation/*drug effects ; Cells, Cultured ; Enzyme-Linked Immunosorbent Assay ; Humans ; Immunohistochemistry ; Mesenchymal Stem Cells/*cytology/*drug effects ; Myocytes, Smooth Muscle/*cytology/*drug effects ; Phosphorylcholine/*analogs & derivatives/pharmacology ; Pyridines/pharmacology ; Simvastatin/*pharmacology ; Sphingosine/*analogs & derivatives/pharmacology ; rhoA GTP-Binding Protein/antagonists & inhibitors/metabolism

Amides/pharmacology ; Blotting, Western ; Cell Differentiation/*drug effects ; Cells, Cultured ; Enzyme-Linked Immunosorbent Assay ; Humans ; Immunohistochemistry ; Mesenchymal Stem Cells/*cytology/*drug effects ; Myocytes, Smooth Muscle/*cytology/*drug effects ; Phosphorylcholine/*analogs & derivatives/pharmacology ; Pyridines/pharmacology ; Simvastatin/*pharmacology ; Sphingosine/*analogs & derivatives/pharmacology ; rhoA GTP-Binding Protein/antagonists & inhibitors/metabolism

3

Cite

Cite

Copy

Share

Share

Copy

The presence of high level soluble herpes virus entry mediator in sera of gastric cancer patients.

Sook Kyoung HEO ; Seong A JU ; Gyu Yeol KIM ; Sang Min PARK ; Sung Hun BACK ; Neung Hwa PARK ; Young Joo MIN ; Won G AN ; Thu Ha NGUYEN ; Sun Min KIM ; Byung Sam KIM

Experimental & Molecular Medicine.2012;44(2):149-158. doi:10.3858/emm.2012.44.2.010

The development of gastric cancer (GC) is closely related to chronic inflammation caused by Helicobacter pylori infection, and herpes virus entry mediator (HVEM) is a receptor expressed on the surface of leukocytes that mediates potent inflammatory responses in animal models. However, the role of HVEM in human GC has not been studied. Previously, we showed that the interaction of HVEM on human leukocytes with its ligand LIGHT induces intracellular calcium mobilization, which results in inflammatory responses including induction of proinflammatory cytokine production and anti-bacterial activities. In this study, we report that leukocytes from GC patients express lower levels of membrane HVEM (mHVEM) and have lower LIGHT-induced bactericidal activities than those from healthy controls (HC). In contrast, levels of soluble HVEM (sHVEM) in the sera of GC patients were significantly higher than in those of HC. We found that monocyte membrane-bound HVEM is released into the medium when cells are activated by proinflammatory cytokines such as TNF-alpha and IL-8, which are elevated in the sera of GC patients. mHVEM level dropped in parallel with the release of sHVEM, and release was completely blocked by the metalloprotease inhibitor, GM6001. We also found that the low level of mHVEM on GC patient leukocytes was correlated with low LIGHT-induced bactericidal activities against H. pylori and S. aureus and production of reactive oxygen species. Our results indicate that mHVEM on leukocytes and sHVEM in sera may contribute to the development and/or progression of GC.
Aged ; Cells, Cultured ; Enzyme-Linked Immunosorbent Assay ; Female ; Flow Cytometry ; Humans ; Male ; Middle Aged ; Monocytes/metabolism ; Neutrophils/metabolism ; Reactive Oxygen Species/metabolism ; Receptors, Tumor Necrosis Factor, Member 14/*blood ; Stomach Neoplasms/*blood/metabolism ; Tumor Necrosis Factor Ligand Superfamily Member 14/blood

Aged ; Cells, Cultured ; Enzyme-Linked Immunosorbent Assay ; Female ; Flow Cytometry ; Humans ; Male ; Middle Aged ; Monocytes/metabolism ; Neutrophils/metabolism ; Reactive Oxygen Species/metabolism ; Receptors, Tumor Necrosis Factor, Member 14/*blood ; Stomach Neoplasms/*blood/metabolism ; Tumor Necrosis Factor Ligand Superfamily Member 14/blood

4

Cite

Cite

Copy

Share

Share

Copy

Increased p190RhoGEF expression in activated B cells correlates with the induction of the plasma cell differentiation.

Yun Jung HA ; Ji Hye JEONG ; Yuna PARK ; Jong Ran LEE

Experimental & Molecular Medicine.2012;44(2):138-148. doi:10.3858/emm.2012.44.2.009

Previously, we demonstrated that the p190 Rho guanine nucleotide exchange factor (p190RhoGEF) was induced following CD40 stimulation of B cells. In this study, we examined whether p190RhoGEF and a downstream effector molecule RhoA are required for B cell differentiation. Expression of p190RhoGEF positively correlated with the expression of surface markers and transcriptional regulators that are characteristic of mature B cells with plasma cell (PC) phenotypes. Moreover, either the overexpression of p190RhoGEF or the expression of a constitutively active RhoA drove cellular differentiation toward PC phenotypes. B cell maturation was abrogated in cells that overexpressed p190RhoGEF and a dominant-negative form of RhoA simultaneously. CD40-mediated maturation events were also abrogated in cells that overexpressed either dominant-negative p190RhoGEF or RhoA. Together, these data provide evidence that p190RhoGEF signaling through RhoA in CD40-activated B cells drives the induction of the PC differentiation.
Animals ; B-Lymphocytes/*cytology/*metabolism ; Cell Differentiation/genetics/*physiology ; Cell Line ; Cells, Cultured ; Female ; Guanine Nucleotide Exchange Factors/genetics/*metabolism ; Humans ; Lymphocyte Activation/genetics/*physiology ; Mice ; Mice, Inbred BALB C ; Plasma Cells/*cytology/*metabolism ; rhoA GTP-Binding Protein/genetics/metabolism

Animals ; B-Lymphocytes/*cytology/*metabolism ; Cell Differentiation/genetics/*physiology ; Cell Line ; Cells, Cultured ; Female ; Guanine Nucleotide Exchange Factors/genetics/*metabolism ; Humans ; Lymphocyte Activation/genetics/*physiology ; Mice ; Mice, Inbred BALB C ; Plasma Cells/*cytology/*metabolism ; rhoA GTP-Binding Protein/genetics/metabolism

5

Cite

Cite

Copy

Share

Share

Copy

Identification of novel peptides that stimulate human neutrophils.

Geon Ho BAE ; Ha Young LEE ; Young Su JUNG ; Jae Woong SHIM ; Sang Doo KIM ; Suk Hwan BAEK ; Jae Young KWON ; Joon Seong PARK ; Yoe Sik BAE

Experimental & Molecular Medicine.2012;44(2):130-137. doi:10.3858/emm.2012.44.2.008

Neutrophils play a key role in innate immunity, and the identification of new stimuli that stimulate neutrophil activity is a very important issue. In this study, we identified three novel peptides by screening a synthetic hexapeptide combinatorial library. The identified peptides GMMWAI, MMHWAM, and MMHWFM caused an increase in intracellular Ca2+ in a concentration-dependent manner via phospholipase C activity in human neutrophils. The three peptides acted specifically on neutrophils and monocytes and not on other non-leukocytic cells. As a physiological characteristic of the peptides, we observed that the three peptides induced chemotactic migration of neutrophils as well as stimulated superoxide anion production. Studying receptor specificity, we observed that two of the peptides (GMMWAI and MMHWFM) acted on formyl peptide receptor (FPR)1 while the other peptide (MMHWAM) acted on FPR2. Since the three novel peptides were specific agonists for FPR1 or FPR2, they might be useful tools to study FPR1- or FPR2-mediated immune response and signaling.
Animals ; Calcium/metabolism ; Cell Line ; Cells, Cultured ; Chemotaxis, Leukocyte/drug effects ; Humans ; Mice ; NIH 3T3 Cells ; Neutrophils/*cytology/*drug effects ; PC12 Cells ; Peptides/*pharmacology ; Rats ; Receptors, Formyl Peptide/agonists

Animals ; Calcium/metabolism ; Cell Line ; Cells, Cultured ; Chemotaxis, Leukocyte/drug effects ; Humans ; Mice ; NIH 3T3 Cells ; Neutrophils/*cytology/*drug effects ; PC12 Cells ; Peptides/*pharmacology ; Rats ; Receptors, Formyl Peptide/agonists

6

Cite

Cite

Copy

Share

Share

Copy

Genetic association of the EGR2 gene with bipolar disorder in Korea.

Se Hyun KIM ; Joo Youn SONG ; Eun Jeong JOO ; Kyu Young LEE ; Soon Young SHIN ; Young Han LEE ; Yong Min AHN ; Yong Sik KIM

Experimental & Molecular Medicine.2012;44(2):121-129. doi:10.3858/emm.2012.44.2.007

The early growth response gene 2 (EGR2) is located at chromosome 10q21, one of the susceptibility loci in bipolar disorder (BD). EGR2 is involved in cognitive function, myelination, and signal transduction related to neuregulin-ErbB receptor, Bcl-2 family proteins, and brain-derived neurotrophic factor. This study investigated the genetic association of the EGR2 gene with BD and schizophrenia (SPR) in Korea. In 946 subjects (350 healthy controls, 352 patients with BD, and 244 with SPR), nine single nucleotide polymorphisms (SNPs) in the EGR2 gene region were genotyped. Five SNPs showed nominally significant allelic associations with BD (rs2295814, rs61865882, rs10995315, rs2297488, and rs2297489), and the positive associations of all except rs2297488 remained significant after multiple testing correction. Linkage disequilibrium structure analysis revealed two haplotype blocks. Among the common identified haplotypes (frequency > 5%), 'T-G-A-C-T (block 1)' and 'A-A-G-C (block 2)' haplotypes were over-represented, while 'C-G-G-T-T (block 1)' haplotype was under-represented in BD. In contrast, no significant associations were found with SPR. Although an extended analysis with a larger sample size or independent replication is required, these findings suggest a genetic association of EGR2 with BD. Combined with a plausible biological function of EGR2, the EGR2 gene is a possible susceptibility gene in BD.
Adult ; Bipolar Disorder/*genetics ; Early Growth Response Protein 2/*genetics ; Female ; Genetic Predisposition to Disease/genetics ; Genotype ; Haplotypes/genetics ; Humans ; Korea ; Linkage Disequilibrium/genetics ; Male ; Polymorphism, Single Nucleotide/genetics ; Schizophrenia/genetics

Adult ; Bipolar Disorder/*genetics ; Early Growth Response Protein 2/*genetics ; Female ; Genetic Predisposition to Disease/genetics ; Genotype ; Haplotypes/genetics ; Humans ; Korea ; Linkage Disequilibrium/genetics ; Male ; Polymorphism, Single Nucleotide/genetics ; Schizophrenia/genetics

7

Cite

Cite

Copy

Share

Share

Copy

Autophagy and cancer.

Kyeong Sook CHOI

Experimental & Molecular Medicine.2012;44(2):109-120. doi:10.3858/emm.2012.44.2.033

Basal autophagy plays a critical role in maintaining cellular homeostasis and genomic integrity by degrading aged or malfunctioning organelles and damaged or misfolded proteins. However, autophagy also plays a complicated role in tumorigenesis and treatment responsiveness. It can be tumor-suppressing during the early stages of tumorigenesis (i.e., it is an anti-tumor mechanism), as reduced autophagy is found in tumor cells and may be associated with malignant transformation. In this case, induction of autophagy would seem to be beneficial for cancer prevention. In established tumors, however, autophagy can be tumor-promoting (i.e., it is a pro-tumor mechanism), and cancer cells can use enhanced autophagy to survive under metabolic and therapeutic stress. The pharmacological and/or genetic inhibition of autophagy was recently shown to sensitize cancer cells to the lethal effects of various cancer therapies, including chemotherapy, radiotherapy and targeted therapies, suggesting that suppression of the autophagic pathway may represent a valuable sensitizing strategy for cancer treatments. In contrast, excessive stimulation of autophagy may also provide a therapeutic strategy for treating resistant cancer cells having high apoptotic thresholds. In order for us to develop successful autophagy-modulating strategies against cancer, we need to better understand how the roles of autophagy differ depending on the tumor stage, cell type and/or genetic factors, and we need to determine how specific pathways of autophagy are activated or inhibited by the various anti-cancer therapies.
Anticarcinogenic Agents/therapeutic use ; Autophagy/*physiology ; Cell Transformation, Neoplastic/drug effects ; Humans ; Neoplasms/*drug therapy/metabolism/*pathology

Anticarcinogenic Agents/therapeutic use ; Autophagy/*physiology ; Cell Transformation, Neoplastic/drug effects ; Humans ; Neoplasms/*drug therapy/metabolism/*pathology

8

Cite

Cite

Copy

Share

Share

Copy

Autophagy and bacterial infectious diseases.

Jae Min YUK ; Tamotsu YOSHIMORI ; Eun Kyeong JO

Experimental & Molecular Medicine.2012;44(2):99-108. doi:10.3858/emm.2012.44.2.032

Autophagy is a housekeeping process that maintains cellular homeostasis through recycling of nutrients and degradation of damaged or aged cytoplasmic constituents. Over the past several years, accumulating evidence has suggested that autophagy can function as an intracellular innate defense pathway in response to infection with a variety of bacteria and viruses. Autophagy plays a role as a specialized immunologic effector and regulates innate immunity to exert antimicrobial defense mechanisms. Numerous bacterial pathogens have developed the ability to invade host cells or to subvert host autophagy to establish a persistent infection. In this review, we have summarized the recent advances in our understanding of the interaction between antibacterial autophagy (xenophagy) and different bacterial pathogens.
Animals ; Autophagy/*physiology ; Bacterial Infections/*immunology/metabolism ; Humans ; Immunity, Innate/physiology ; Reactive Oxygen Species/metabolism

Animals ; Autophagy/*physiology ; Bacterial Infections/*immunology/metabolism ; Humans ; Immunity, Innate/physiology ; Reactive Oxygen Species/metabolism

9

Cite

Cite

Copy

Share

Share

Copy

Neuronal autophagy and neurodegenerative diseases.

Jin H SON ; Jung Hee SHIM ; Kyung Hee KIM ; Ji Young HA ; Ji Young HAN

Experimental & Molecular Medicine.2012;44(2):89-98. doi:10.3858/emm.2012.44.2.031

Autophagy is a dynamic cellular pathway involved in the turnover of proteins, protein complexes, and organelles through lysosomal degradation. The integrity of postmitotic neurons is heavily dependent on high basal autophagy compared to non-neuronal cells as misfolded proteins and damaged organelles cannot be diluted through cell division. Moreover, neurons contain the specialized structures for intercellular communication, such as axons, dendrites and synapses, which require the reciprocal transport of proteins, organelles and autophagosomes over significant distances from the soma. Defects in autophagy affect the intercellular communication and subsequently, contributing to neurodegeneration. The presence of abnormal autophagic activity is frequently observed in selective neuronal populations afflicted in common neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. These observations have provoked controversy regarding whether the increase in autophagosomes observed in the degenerating neurons play a protective role or instead contribute to pathogenic neuronal cell death. It is still unknown what factors may determine whether active autophagy is beneficial or pathogenic during neurodegeneration. In this review, we consider both the normal and pathophysiological roles of neuronal autophagy and its potential therapeutic implications for common neurodegenerative diseases.
Alzheimer Disease/metabolism/pathology/physiopathology ; Animals ; Autophagy/*physiology ; Humans ; Huntington Disease/metabolism/pathology/physiopathology ; Models, Biological ; Neurodegenerative Diseases/metabolism/*pathology/physiopathology ; Neurons/*cytology ; Parkinson Disease/metabolism/pathology/physiopathology

Alzheimer Disease/metabolism/pathology/physiopathology ; Animals ; Autophagy/*physiology ; Humans ; Huntington Disease/metabolism/pathology/physiopathology ; Models, Biological ; Neurodegenerative Diseases/metabolism/*pathology/physiopathology ; Neurons/*cytology ; Parkinson Disease/metabolism/pathology/physiopathology

10

Cite

Cite

Copy

Share

Share

Copy

Role of autophagy in diabetes and endoplasmic reticulum stress of pancreatic beta-cells.

Wenying QUAN ; Yu Mi LIM ; Myung Shik LEE

Experimental & Molecular Medicine.2012;44(2):81-88. doi:10.3858/emm.2012.44.2.030

Type 2 diabetes mellitus is characterized by insulin resistance and failure of pancreatic beta-cells producing insulin. Autophagy plays a crucial role in cellular homeostasis through degradation and recycling of organelles such as mitochondria or endoplasmic reticulum (ER). Here we discussed the role of beta-cell autophagy in development of diabetes, based on our own studies using mice with beta-cell-specific deletion of Atg7 (autophagy-related 7), an important autophagy gene, and studies by others. beta-cell-specific Atg7-null mice showed reduction in beta-cell mass and pancreatic insulin content. Insulin secretory function ex vivo was also impaired, which might be related to organelle dysfunction associated with autophagy deficiency. As a result, beta-cell-specific Atg7-null mice showed hypoinsulinemia and hyperglycemia. However, diabetes never developed in those mice. Obesity and/or lipid are physiological ER stresses that can precipitate beta-cell dysfunction. Our recent studies showed that beta-cell-specific Atg7-null mice, when bred with ob/ob mice, indeed become diabetic. Thus, autophagy deficiency in beta-cells could be a precipitating factor in the progression from obesity to diabetes due to inappropriate response to obesity-induced ER stress.
Animals ; Autophagy/genetics/*physiology ; Diabetes Mellitus/genetics/*metabolism ; Endoplasmic Reticulum Stress/genetics/*physiology ; Humans ; Insulin-Secreting Cells/*metabolism

Animals ; Autophagy/genetics/*physiology ; Diabetes Mellitus/genetics/*metabolism ; Endoplasmic Reticulum Stress/genetics/*physiology ; Humans ; Insulin-Secreting Cells/*metabolism

Country

Republic of Korea

Publisher

Korean Society of Medical Biochemistry and Molecular Biology.

ElectronicLinks

http://www.ncbi.nlm.nih.gov/pmc/journals/872/

Editor-in-chief

Dae-Myung Jue

E-mail

Abbreviation

Exp Mol Med

Vernacular Journal Title

ISSN

1226-3613

EISSN

Year Approved

2007

Current Indexing Status

Currently Indexed

Start Year

1964

Description

Experimental & Molecular Medicine (EMM) is Korea’s first biochemistry journal (founded in 1964) and is relaunched in 1996 as an Open Access, fully peer-reviewed international journal devoted to publishing the latest and most important advances in genetic, molecular and cellular studies of human physiology and diseases. The journal aims to communicate the improved clinical benefits for human health from the experimental and translational research performed using molecular tools. Areas that are covered include, but are not limited to, cancer biology, immunology, neuroscience, cardiovascular diseases, genetics and genomics, gene therapy and stem cells and regenerative medicine.

Related Sites

WHO WPRO GIM

Help Accessibility
DCMS Web Policy
CJSS Privacy Policy

Powered by IMICAMS( 备案号: 11010502037788, 京ICP备10218182号-8)

Successfully copied to clipboard.